Sugi Predict

Sugi Predict / Compounds / Hypoxanthine

Hypoxanthine

Hypoxanthine

SCHEMBL29467372

CCN(CC)CC.O=c1[nH]cnc2[nH]cnc12

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ KDM4A O75164 1/20 0.40
▸ KDM4B O94953 1/20 0.40
▸ KDM5C P41229 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PDPK1 O15530 4/20 0.39
▸ PARP1 P09874 2/20 0.38
▸ PNP P00491 1/20 0.37
▸ ADORA2A P29274 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ ADRA1A P35348 1/20 0.37
▸ XDH P47989 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hypoxanthine SCHEMBL30324467 1.00 CYP1A2 (0.41) CYP1A2CYP2D6KDM4AKDM4BKDM5C
Hypoxanthine SCHEMBL822613 0.84 TSHR (0.47) RAB9AKDM4EGAAHPGDHSD17B10
Hypoxanthine SCHEMBL30266940 0.82 TSHR (0.45) RAB9AKDM4EGAAHPGDHSD17B10
Adenine SCHEMBL4648928 0.74 ADORA2A (0.40) ADORA2ALMNAXDHALDH1A1STING1
SCHEMBL30324403 0.73 CYP1A2 (0.54) CYP1A2CYP2D6RAB9AKDM4EGAA
SCHEMBL30324779 0.72 CYP1A2 (0.52) CYP1A2CYP2D6RAB9AKDM4EGAA
SCHEMBL30500527 0.72 CYP1A2 (0.36) CYP1A2CYP2D6KDM4AKDM4BKDM5C
SCHEMBL1993929 0.70 ADORA2A (0.40) CYP1A2CYP2D6KDM4AKDM4BKDM5C
Hypoxanthine SCHEMBL31181347 0.69 ACHE (0.38) RAB9AKDM4EHPGDPDPK1PARP1
Hypoxanthine SCHEMBL29533161 0.69 TSHR (0.41) RAB9AKDM4EGAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435104-B2 Cyclic dinucleotides as sting agonists BEIGENE, LTD. (KY) 2025-10-07 — — US disclosed
CN-114206898-B Cyclic dinucleotides as STING agonists 百济神州有限公司 2024-06-25 — — CN disclosed
CN-110325543-B Cyclic dinucleotides as STING (stimulator of interferon genes) agonists 武田药品工业株式会社 2023-03-31 — — CN disclosed
US-20220251135-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS BEONE MEDICINES I GMBH (CH) 2022-08-11 — — US disclosed
CN-114206898-A Cyclic dinucleotides as STING agonists 百济神州有限公司 2022-03-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251135-A1 CYCLIC DINUCLEOTIDES AS STING AGONISTS STING1, CGAS, MAVS CYP1A2 3432/4885CYP2D6 3842/4885KDM4A 2813/4885
US-12435104-B2 Cyclic dinucleotides as sting agonists STING1, CGAS, MAVS CYP1A2 3432/4885CYP2D6 3842/4885KDM4A 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.